|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:phenothiazine_derivative
|
|
gptkbp:ATCCode
|
N05AA01
|
|
gptkbp:brand
|
gptkb:Largactil
gptkb:Thorazine
|
|
gptkbp:CASNumber
|
50-53-3
|
|
gptkbp:chemicalFormula
|
C17H19ClN2S
|
|
gptkbp:color
|
white to pale yellow (powder)
|
|
gptkbp:contraindication
|
coma
bone marrow depression
CNS depression
|
|
gptkbp:developedBy
|
gptkb:Rhône-Poulenc
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Charpentier
|
|
gptkbp:discoveredIn
|
1950
|
|
gptkbp:eliminationHalfLife
|
30 hours
|
|
gptkbp:excretion
|
urine
bile
feces
|
|
gptkbp:firstAntipsychotic
|
true
|
|
gptkbp:includedIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
antagonist at histamine, muscarinic, and adrenergic receptors
|
|
gptkbp:MeSH_ID
|
D002811
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
318.86 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
2726
DB00477
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
weight gain
hypotension
sedation
photosensitivity
extrapyramidal symptoms
neuroleptic malignant syndrome
anticholinergic effects
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
U3P01618RT
|
|
gptkbp:usedFor
|
bipolar disorder
nausea
schizophrenia
vomiting
tetanus
acute psychosis
intractable hiccups
manic phase of bipolar disorder
preoperative sedation
|
|
gptkbp:bfsParent
|
gptkb:IG_Farben
gptkb:Thorazine
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
chlorpromazine
|